# EDGAR Filing Document

**Accession Number:** 0001652130
**File Stem:** 0001193125-25-317551
**Filing Date:** 2025-12
**Character Count:** 8051
**Document Hash:** 45e7ff4eaa2f271d8ac412fe1960cda1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-317551.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001193125-25-317551

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251211

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LEONARD JOHN M
- **CENTRAL INDEX KEY:** 0001563584

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37766
- **FILM NUMBER:** 251568186

**MAIL ADDRESS:**
- **STREET 1:** C/O INTELLIA THERAPEUTICS INC
- **STREET 2:** 40 ERIE STREET, SUITE 130
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER NAME:**
- **FORMER CONFORMED NAME:** LEONARD JOHN M.
- **DATE OF NAME CHANGE:** 20121204
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Intellia Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001652130
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 364785571
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 40 ERIE STREET
- **STREET 2:** SUITE 130
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-285-6200

**MAIL ADDRESS:**
- **STREET 1:** 40 ERIE STREET
- **STREET 2:** SUITE 130
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LEONARD JOHN M<br><sub>(Last) (First) (Middle)</sub><br>C/O INTELLIA THERAPEUTICS, INC.<br>40 ERIE STREET; SUITE 130<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02139<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-11 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Intellia Therapeutics, Inc. [ NTLA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-12-11 |  | M |  | 49959 | A | $6.83 | 1127074 | D |  |
| Common Stock | 2025-12-11 |  | S<sup>(1)</sup> |  | 49959 | D | 9.49<sup>(2)</sup> | 1077115 | D |  |
| Common Stock | 2025-12-11 |  | S<sup>(1)</sup> |  | 32832 | D | 9.47<sup>(3)</sup> | 1044283 | D |  |
| Common Stock | 2025-12-11 |  | S<sup>(1)</sup> |  | 5355 | D | 9.59<sup>(4)</sup> | 1038928 | D |  |
| Common Stock | 2025-12-12 |  | M |  | 8557 | A | $6.83 | 1047485 | D |  |
| Common Stock |  |  |  |  |  |  |  | 58415 | I | By Trust<sup>(5)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | $6.83 | 2025-12-11 |  | M |  |  | 49959 | <sup>(6)</sup> | 2026-02-03 | Common Stock | 49959 | $0.00 | 8557 | D |  |
| Stock Option (right to buy) | $6.83 | 2025-12-12 |  | M |  |  | 8557 | <sup>(6)</sup> | 2026-02-03 | Common Stock | 8557 | $0.00 | 0 | D |  |

---

### Footnotes:

(1) The sales reported on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025.

(2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.33 to $9.64, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.

(3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.30 to $9.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.

(4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.57 to $9.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2025 at each separate price.

(5) Shares held by the John M. Leonard 2015 Irrevocable Trust.

(6) The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested in full as of December 11, 2025.

**Signature:** /s/ James Basta, attorney-in-fact  
**Date:** 2025-12-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**